FBC
EDIT icon

Fairfield, Bush & Co’s Editas Medicine EDIT Stock Holding History

Fairfield, Bush & Co’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,000
Closed -$534K – 140
2021
Q3 		$534K Buy
+13,000
New +$712K 0.17% 109
2021
Q2 		– Sell
-6,000
Closed -$252K – 152
2021
Q1 		$252K Hold
6,000
– – 0.07% 146
2020
Q4 		$421K Buy
+6,000
New +$246K 0.12% 114

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fairfield, Bush & Co's EDIT Position: Q4 2021 in Review

Fairfield, Bush & Co sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 13,000 shares — an estimated $534K sold.

Fairfield, Bush & Co first reported a position in EDIT in Q4 2020 and held it in 3 quarters. The position peaked at $534K in Q3 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Fairfield, Bush & Co reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Fairfield, Bush & Co sold 13,000 Editas Medicine shares in Q4 2021, an estimated $534K.
  • Fairfield, Bush & Co first reported a position in Editas Medicine in Q4 2020 and held it in 3 quarters.
  • Fairfield, Bush & Co's Editas Medicine position peaked at $534K in Q3 2021.
  • 305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Fairfield, Bush & Co's 13F filing for Q4 2021, filed 9 Feb 2022.